Sheila Frame: Biosimilars and Cost Reductions for Patients
Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, discusses when patients will see their costs reduced as a result of biosimilars.
Transcript:
Well, it's an immediate opportunity for cost savings. I think from a contracting perspective, as we come into the marketplace, the minute any organization chooses a biosimilar as either a first-line treatment or a second-line treatment or converts from the originator product, then the patient should be seeing those savings immediately.
But, as you know in the US marketplace, transparency isn't necessarily something that everybody's able to get to, right? We can see it, because we contract directly, but the way the US system evolved over time, for lots of good reasons, there's so many people in the middle where the product actually goes through these middlemen, then everyone kind of takes their share. By the time it gets to the patient, it's a $25 copay or it's a $50 copay or it's a deductible.
So I believe that the more transparency that we can bring to the system overall, then the sooner patients are going to see the value and benefit from it.
So, because we have this great evidence now to suggest that biosimilars are just as good from an efficacy and safety perspective, then I think patients are going to be willing to take them on and say, hey, I want to make sure that I get access and that I get access at a fair price and that the system benefits from these products once they're available.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
November 9th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
April 12th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.
